In addition, hesperidin regulates hepatic cholesterol synthesis by inhibiting the activity of 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase [4, 5].
Park et al., "Plasma and hepatic cholesterol and hepatic activities of 3-hydroxy-3-methyl-glutaryl-CoA reductase and acyl CoA: cholesterol transferase are lower in rats fed citrus peel extract or a mixture of citrus bioflavonoids," The Journal of Nutrition, vol.
E, Cholesterol metabolism: sterol regulatory element-binding protein 2 (SREBP-2); liver X receptor alpha (LXR-[alpha]); low-density lipoprotein receptor (LDL-R); acetyl-CoA acetyltransferase 1 (ACAT-1); 3-hydroxy-3-methyl-glutaryl-CoA
These findings might be due to blocking enzymes such as 3-hydroxy-3-methyl-glutaryl-CoA
reductase (HMGCR), fatty acid synthase and cholesterol 7- alpha-hydroxylase.26 The reversal of glycogen depletion was seen in another study, as supplementation with black tea extract restored the glycogen content in hepatocytes in ethanol with high-fat diet-induced hepatotoxicity in male Wistar rats.25
) reductase were isolated from hepatic microsomes by preparative ultracentrifugation and determined as previously reported .
The mechanism of tocotrienol's hypolipidemic action involves posttranscriptional suppression of HMGR (3-hydroxy-3-methyl-glutaryl-CoA
reductase--the enzyme/protein responsible for the body's cholesterol production) via controlled degradation of the reductase protein.
Subgroup analysis was performed for several medication groups (beta blockers, 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitors, antiplatelets and anticoagulants) due to the possible clinical implications that missed doses of these medications may have (5-9).
Secondary hypotheses were that pharmacist supplementary prescribing reduces the number of medications charted at an incorrect dose or frequency and reduces the number of missed medication doses postoperatively of significant medications such as beta blockers, 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitors, antiplatelets and anticoagulants.
Diplopia, blepharoptosis, and ophthalmoplegia and 3-hydroxy-3-methyl-glutaryl-CoA
reductase inhibitor use.
) reductase inhibitors (statins) have no demonstrable efficacy in modifying Lp(a) levels.